Document Detail


Artificial surfactant attenuates hyperoxic lung injury in primates. I. Physiology and biochemistry.
MedLine Citation:
PMID:  7649917     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Prolonged exposure to O2 causes diffuse alveolar damage and surfactant dysfunction that contribute to the pathophysiology of hyperoxic lung injury. We hypothesized that exogenous surfactant would improve lung function during O2 exposure in primates. Sixteen healthy male baboons (10-15 kg) were anesthetized and mechanically ventilated for 96 h. The animals received either 100% O2 (n = 6) or 100% O2 plus aerosolized artificial surfactant (Exosurf; n = 5). A third group of animals (n = 5) was ventilated with an inspired fraction of O2 of 0.21 to control for the effects of sedation and mechanical ventilation. Hemodynamic parameters were obtained every 12 h, and ventilation-perfusion distribution (VA/Q) was measured daily using a multiple inert-gas elimination technique. Positive end-expiratory pressure was kept at 2.5 cmH2O and was intermittently raised to 10 cmH2O for 30 min to obtain additional measurements of VA/Q. After the experiments, lungs were obtained for biochemical and histological assessment of injury. O2 exposures altered hemodynamics, progressively worsened VA/Q, altered lung phospholipid composition, and produced severe lung edema. Artificial surfactant therapy significantly increased disaturated phosphatidylcholine in lavage fluid and improved intrapulmonary shunt, arterial PO2, and lung edema. Surfactant also enhanced the shunt-reducing effect of positive end-expiratory pressure. We conclude that an aerosolized protein-free surfactant decreased the progression of pulmonary O2 toxicity in baboons.
Authors:
Y C Huang; A C Sane; S G Simonson; T A Fawcett; R E Moon; P J Fracica; M G Menache; C A Piantadosi; S L Young
Related Documents :
10759447 - Preservation of intraalveolar surfactant in a rat lung ischaemia/reperfusion injury model.
7313347 - Lung compliance and alveolar expansion in the artificially ventilated premature newborn...
8713657 - Rapid tracheal infusion of surfactant versus bolus instillation in rabbits: effects on ...
12414037 - The role of tissue reperfusion in the reexpansion injury of the lungs.
22481227 - Asynchrony, neural drive, ventilatory variability and comfort: nava versus pressure sup...
9952007 - Significant reduction in circuit pressure with modified plasma separation chamber for a...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of applied physiology (Bethesda, Md. : 1985)     Volume:  78     ISSN:  8750-7587     ISO Abbreviation:  J. Appl. Physiol.     Publication Date:  1995 May 
Date Detail:
Created Date:  1995-09-27     Completed Date:  1995-09-27     Revised Date:  2013-09-26    
Medline Journal Info:
Nlm Unique ID:  8502536     Medline TA:  J Appl Physiol (1985)     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1816-22     Citation Subset:  IM; S    
Affiliation:
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Drug Combinations
Enzyme-Linked Immunosorbent Assay
Fatty Alcohols / administration & dosage,  metabolism,  therapeutic use*
Hemodynamics / drug effects,  physiology
Lung Diseases / drug therapy*,  metabolism,  physiopathology
Male
Oxygen / blood,  toxicity*
Papio
Phospholipids / metabolism
Phosphorylcholine*
Polyethylene Glycols / administration & dosage,  metabolism,  therapeutic use*
Positive-Pressure Respiration
Proteolipids / metabolism
Pulmonary Edema / drug therapy,  physiopathology
Pulmonary Surfactant-Associated Proteins
Pulmonary Surfactants / administration & dosage,  metabolism,  therapeutic use*
Respiratory Mechanics / drug effects,  physiology
Grant Support
ID/Acronym/Agency:
P01-HL-31992/HL/NHLBI NIH HHS; T32-HL-07528/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Drug Combinations; 0/Fatty Alcohols; 0/Phospholipids; 0/Polyethylene Glycols; 0/Proteolipids; 0/Pulmonary Surfactant-Associated Proteins; 0/Pulmonary Surfactants; 107-73-3/Phosphorylcholine; 7782-44-7/Oxygen; 99732-49-7/dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharyngeal narrowing/occlusion during central sleep apnea.
Next Document:  Artificial surfactant attenuates hyperoxic lung injury in primates. II. Morphometric analysis.